• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过靶向肿瘤微环境克服表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药性

Overcoming EGFR-TKI resistance by targeting the tumor microenvironment.

作者信息

Zhang Jinsong, Vokes Natalie, Li Man, Xu Jiachen, Bai Hua, Wang Jie, Wang Zhijie, Zhang Jianjun

机构信息

State Key Laboratory of Molecular Oncology, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuannanli, Chaoyang District, Beijing 100021, China.

Department of Thoracic/Head and Neck Medical Oncology, Department of Genomic Medicine, The Lung Cancer Interception Program, The Lung Cancer Genomics Program, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Chin Med J Pulm Crit Care Med. 2024 Sep 16;2(3):151-161. doi: 10.1016/j.pccm.2024.08.002. eCollection 2024 Sep.

DOI:10.1016/j.pccm.2024.08.002
PMID:39403414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11471126/
Abstract

Targeted therapy has ushered in a new era of precision medicine for non-small cell lung cancer (NSCLC). Currently, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) stand as the recommended first-line therapy for advanced NSCLC harboring sensitive mutations. Nevertheless, most patients inevitably confront the challenge of drug resistance. This phenomenon arises not solely from intrinsic alterations within cancer cells but also from the intricate dynamics of the tumor microenvironment and the complex interactions that occur between cancer cells and their immediate surroundings. This review consolidates the current knowledge regarding EGFR-TKI resistance mechanisms, with a specific emphasis on unraveling the role played by the tumor microenvironment. In addition, the review delineates strategic approaches to surmount TKI resistance, thereby enriching the understanding of the interplay between therapeutic agents and the intricate milieu surrounding cancer cells.

摘要

靶向治疗开创了非小细胞肺癌(NSCLC)精准医学的新时代。目前,表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKIs)是携带敏感突变的晚期NSCLC的推荐一线治疗药物。然而,大多数患者不可避免地面临耐药挑战。这种现象不仅源于癌细胞内部的内在改变,还源于肿瘤微环境的复杂动态以及癌细胞与其周围环境之间发生的复杂相互作用。本综述整合了关于EGFR-TKI耐药机制的现有知识,特别强调揭示肿瘤微环境所起的作用。此外,该综述还阐述了克服TKI耐药的策略方法,从而加深了对治疗药物与癌细胞周围复杂环境之间相互作用的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05d/11471126/435947d41ad5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05d/11471126/142c72ad4dbb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05d/11471126/0e0cecb072bb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05d/11471126/435947d41ad5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05d/11471126/142c72ad4dbb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05d/11471126/0e0cecb072bb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b05d/11471126/435947d41ad5/gr3.jpg

相似文献

1
Overcoming EGFR-TKI resistance by targeting the tumor microenvironment.通过靶向肿瘤微环境克服表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药性
Chin Med J Pulm Crit Care Med. 2024 Sep 16;2(3):151-161. doi: 10.1016/j.pccm.2024.08.002. eCollection 2024 Sep.
2
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.表皮生长因子受体酪氨酸激酶抑制剂治疗前后表皮生长因子受体突变的非小细胞肺癌中的肿瘤免疫微环境:一篇叙述性综述
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
3
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.表皮生长因子受体突变(EGFR)检测对晚期非小细胞肺癌患者使用表皮生长因子受体靶向酪氨酸激酶抑制剂(TKI)药物疗效的预测:一项循证分析
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.
4
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.针对非小细胞肺癌细胞中的表皮生长因子受体:RNA 干扰与酪氨酸激酶抑制剂或西妥昔单抗联合的效果。
BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28.
5
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.EGFR-TKI 重挑战治疗在携带药物敏感 EGFR 突变的老年晚期非小细胞肺癌患者中的疗效和安全性。
Medicina (Kaunas). 2021 Sep 3;57(9):929. doi: 10.3390/medicina57090929.
6
Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells .高胰岛素血症通过PI3K/AKT途径对非小细胞肺癌细胞获得性表皮生长因子受体-酪氨酸激酶抑制剂耐药性的影响
Oncol Lett. 2020 Nov;20(5):206. doi: 10.3892/ol.2020.12069. Epub 2020 Sep 8.
7
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体(EGFR)突变阳性非小细胞肺癌(NSCLC)中酪氨酸激酶抑制剂(TKI)的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
8
Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.胰岛素样生长因子1受体(IGF-1R)的表达预示着携带激活型表皮生长因子受体(EGFR)突变的非小细胞肺癌患者对表皮生长因子受体(EGFR)酪氨酸激酶抑制剂反应不佳。
Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.
9
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.非小细胞肺癌患者获得性表皮生长因子受体酪氨酸激酶抑制剂耐药的临床策略
Oncotarget. 2017 Aug 4;8(38):64600-64606. doi: 10.18632/oncotarget.19925. eCollection 2017 Sep 8.
10
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.了解 TKI 诱导的肿瘤免疫微环境变化的动态,以提高治疗效果。
J Immunother Cancer. 2024 Jun 21;12(6):e009165. doi: 10.1136/jitc-2024-009165.

引用本文的文献

1
TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition.TLE1通过上皮-间质转化驱动EGFR突变型肺腺癌对EGFR-TKI的耐药性。
Biochem Biophys Res Commun. 2025 Aug 15;775:152146. doi: 10.1016/j.bbrc.2025.152146. Epub 2025 Jun 3.
2
Ethyl acetate extract of : a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC.……的乙酸乙酯提取物:一种针对非小细胞肺癌中耐药性EGFR_T790M突变体的特异性强效抑制剂。 需注意,原文中“Ethyl acetate extract of :”这里冒号前缺少具体所指内容,翻译时只能按省略号表示。
Front Pharmacol. 2025 Apr 29;16:1570108. doi: 10.3389/fphar.2025.1570108. eCollection 2025.
3

本文引用的文献

1
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study.在非小细胞肺癌患者使用酪氨酸激酶抑制剂治疗失败后,联合使用 SNK01(自体自然杀伤细胞)、细胞毒性化疗药物和/或西妥昔单抗的安全性和有效性:非临床小鼠模型和 I/IIa 期临床研究。
J Immunother Cancer. 2024 Mar 27;12(3):e008585. doi: 10.1136/jitc-2023-008585.
2
Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment.NF-κB 和 MAPK 信号通路的异常激活会影响奥希替尼耐药,并影响髓系来源抑制细胞的募集,从而塑造免疫抑制性肿瘤免疫微环境。
Thorac Cancer. 2023 Jul;14(19):1843-1856. doi: 10.1111/1759-7714.14929. Epub 2023 May 23.
3
Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs.
非小细胞肺癌中外显子突变的靶向治疗:LAG-3、TIM-3通路的临床见解及第四代EGFR-TKIs的进展
Med Oncol. 2025 May 5;42(6):196. doi: 10.1007/s12032-025-02755-9.
4
Translational Advances in Oncogene and Tumor-Suppressor Gene Research.癌基因与肿瘤抑制基因研究的转化进展
Cancers (Basel). 2025 Mar 17;17(6):1008. doi: 10.3390/cancers17061008.
5
Modulation of almonertinib resistance in non-small cell lung cancer by cancer-associated fibroblasts through HK2-mediated glycolysis and SKP2 signaling.癌症相关成纤维细胞通过HK2介导的糖酵解和SKP2信号传导对非小细胞肺癌中阿美替尼耐药性的调节
Discov Oncol. 2025 Feb 15;16(1):187. doi: 10.1007/s12672-025-01974-w.
6
CKAP4 is a potential therapeutic target to overcome resistance to EGFR-TKIs in lung adenocarcinoma.细胞骨架相关蛋白4(CKAP4)是克服肺腺癌对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)耐药性的一个潜在治疗靶点。
Genes Genomics. 2025 Mar;47(3):331-340. doi: 10.1007/s13258-024-01606-7. Epub 2024 Dec 20.
Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.通过 STAT3/CD47-SIRPα 轴重编程 TAMs 可促进肺癌对 EGFR-TKIs 的获得性耐药。
Cancer Lett. 2023 Jun 28;564:216205. doi: 10.1016/j.canlet.2023.216205. Epub 2023 May 4.
4
Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of mutant lung cancer.STING 激动剂靶向肿瘤相关巨噬细胞可提高突变型肺癌小鼠模型中奥希替尼的抗肿瘤疗效。
Front Immunol. 2023 Feb 16;14:1077203. doi: 10.3389/fimmu.2023.1077203. eCollection 2023.
5
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.IL6 介导 EMT 相关 TKI 耐药 EGFR 突变 NSCLC 中 T 细胞和 NK 细胞功能的抑制。
Clin Cancer Res. 2023 Apr 3;29(7):1292-1304. doi: 10.1158/1078-0432.CCR-22-3379.
6
Prognostic role of annexin A2 and cancer-associated fibroblasts in advanced non-small cell lung cancer: Implication in epithelial-mesenchymal transition and gefitinib resistance.膜联蛋白A2和癌症相关成纤维细胞在晚期非小细胞肺癌中的预后作用:在上皮-间质转化和吉非替尼耐药中的意义
Pathol Res Pract. 2023 Jan;241:154293. doi: 10.1016/j.prp.2022.154293. Epub 2022 Dec 28.
7
Single-cell transcriptional profiling uncovers the association between EOMESCD8 T cells and acquired EGFR-TKI resistance.单细胞转录组谱分析揭示了 EOMESCD8 T 细胞与获得性 EGFR-TKI 耐药之间的关联。
Drug Resist Updat. 2023 Jan;66:100910. doi: 10.1016/j.drup.2022.100910. Epub 2022 Dec 15.
8
Graph deep learning for the characterization of tumour microenvironments from spatial protein profiles in tissue specimens.基于组织标本空间蛋白质图谱的肿瘤微环境特征的图深度学习。
Nat Biomed Eng. 2022 Dec;6(12):1435-1448. doi: 10.1038/s41551-022-00951-w. Epub 2022 Nov 10.
9
Tumor-associated macrophage-derived exosomes promote EGFR-TKI resistance in non-small cell lung cancer by regulating the AKT, ERK1/2 and STAT3 signaling pathways.肿瘤相关巨噬细胞衍生的外泌体通过调节AKT、ERK1/2和STAT3信号通路促进非小细胞肺癌对EGFR-TKI的耐药性。
Oncol Lett. 2022 Aug 24;24(4):356. doi: 10.3892/ol.2022.13476. eCollection 2022 Oct.
10
Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.阻断 STAT3/IL-4 可通过抑制 M2 巨噬细胞极化克服 EGFR T790M-cis-L792F 诱导的奥希替尼耐药。
EBioMedicine. 2022 Sep;83:104200. doi: 10.1016/j.ebiom.2022.104200. Epub 2022 Aug 3.